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Abstract
Objective: To	 compare	 the	 clinical	 symptomatology	 in	 patients	 with	 Early-Onset 
Schizophrenia	(EOS,	N	=	176),	especially	the	subgroup	Very Early Onset Schizophrenia 
(VEOS)	and	Adult Onset Schizophrenia	(AOS,	N	=	551).
Method: In	 a	 large	French	multicentric	 sample,	 727	 stable	 schizophrenia	patients,	
classified	by	age	at	onset	of	the	disorder,	were	assessed	using	standardized	and	ex-
tensive	clinical	and	neuropsychological	batteries:	AOS	with	onset	≥	18	years	and	EOS	
with	onset	<	18	years	(including	22	VEOS	<	13	years).
Results: The	importance	of	better	diagnosing	EOS	group,	and	in	particularly	VEOS,	
appeared	in	a	longer	DUP	Duration of Untreated Psychosis	(respectively,	2.6	years	±	4.1	
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1 | INTRODUC TION
Classically,	schizophrenia	often	starts	in	adolescence	or	in	young	adults	
(Chen,	Selvendra,	Stewart,	&	Castle,	2018)	and	is	one	of	the	most	com-
mon	 and	 severe	 forms	of	mental	 illness	 (APA,	 2013).	 It	 is	 also	very	
expensive	(Laidi	et	al.,	2018;	Van	Os	&	Kapur,	2009)	for	society	and	
is a major public health concern, especially toward an early diagnosis. 
The	World Health Organization	 (WHO)	 estimated	 that	 schizophrenia	
was	the	5th	leading	worldwide	cause	of	global	disease	burden	(Millier	
et	al.,	2014)	in	2004	among	males,	with	2.8%	of	total	Years Lived With 
Disability	(YLD),	and	6th	among	females,	with	2.6%	of	YLD.	However,	
it	is	not	easy	to	describe	and	define	schizophrenia	from	childhood	to	
adulthood.	Since	the	early	1990s,	definitions	have	tended	to	harmo-
nize,	with	Adult Onset Schizophrenia	(AOS),	where	the	age	of	onset	is	
greater	 than	or	 equal	 18	years,	Early Onset Schizophrenia	 (EOS),	 de-
fined	by	an	onset	strictly	before	the	age	of	18	years,	and	the	subgroup	
Very Early Onset Schizophrenia	 (VEOS),	developing	strictly	before	the	
age	of	13	years	(Werry,	1992).
In	 the	 literature,	 EOS	and	VEOS	are	 associated	with	misdiagno-
sis	 and	 poor	 outcomes	 (Asarnow	 et	 al.,	 1994;	 Gochman,	 Miller,	 &	
Rapoport,	2011;	Gordon	et	al.,	1994;	Kumra	et	al.,	2000;	McKenna	et	
al.,	1994;	Rapoport	&	Gogtay,	2011;	Rapoport	&	Inoff-Germain,	2000;	
Remschmidt	&	Theisen,	2012).	 In	particular,	according	to	the	neuro-
developmental	hypothesis	(Gourion	et	al.,	2004;	Rapoport	&	Gogtay,	
2011;	 Sato,	 Bottlender,	 Schröter,	 &	Möller,	 2004),	 an	 earlier	 age	 at	
onset	 is	 associated	with:	more	 negative	 symptoms	 (Rammou	 et	 al.,	
2019);	more	premorbid	deficits	(Ballageer,	Malla,	Manchanda,	Takhar,	
&	Haricharan,	2005;	Hollis,	2003;	Luoma,	Hakko,	Ollinen,	Järvelin,	&	
Lindeman,	2008);	higher	 levels	of	enuresis	 (Hollis,	2003);	and	higher	
levels	of	autistic	 traits	 (Coulon,	2015).	The	earlier	 the	schizophrenia	
begins,	the	poorer	the	prognosis	and	the	greater	the	severity	(Coulon,	
2015).	However,	few	studies	are	precise	in	the	definitions	with	AOS,	
EOS,	and	VEOS	(see	Table	1):	In	Sato	et	al.	(2004),	earlier-onset	schizo-
phrenia	was	before	40	years	and	before;	Ballageer	et	al.	(2005)	com-
pared	an	onset	of	psychosis	in	adolescence	(ages	15–18)	with	young	
adulthood	 (ages	 19–30);	White,	 Ho,	Ward,	O'Leary,	 and	Andreasen	
(2006)	studied	two	groups,	one	with	an	onset	strictly	before	the	age	
of	20	and	the	other	with	an	onset	after	the	age	of	20;	Schimmelmann,	
Conus,	Cotton,	McGorry,	and	Lambert	(2007),	Luoma	et	al.	(2008),	Joa	
et	al.	(2009),	and	Holmén	et	al.	(2012)	studied	also	two	groups	with	a	
cutoff	close	to	the	age	of	18;	Biswas,	Malhotra,	Malhotra,	and	Gupta	
(2006,	2007)	are	the	only	ones	with	three	groups,	but	with	a	cutoff	
of	14	years	 for	VEOS	and	 small	 samples	 sizes	 (N	=	35	 for	EOS	and	
N	 =	 20	 for	AOS).	 Consequently,	 available	 epidemiologic	 data	 about	
VEOS	are	rare	because	of	differences	in	definition	and	VEOS	seems	to	
occur	very	uncommonly	in	children	younger	than	13	years.	According	
to	 several	 authors	 (Bleuler,	 1972;	 Lutz,	 1972),	 4%	 of	 schizophre-
nia	begin	before	 age	15	 and	0.5%–1%	before	 age	10;	Remschmidt,	
Schulz,	Martin,	Warnke,	and	Trott	(1994)	based	on	these	percentages	
and estimated that, in the general population, 1 child in 10,000 could 
develop	a	schizophrenia,	compared	to	approximatively	1	adult	in	100	
for	this	pathology	(APA,	2000).	In	2011,	the	NIMH	National Institute 
of Mental Health	reference	team	(Gochman	et	al.,	2011)	announced	a	
VEOS	prevalence	of	approximately	1	 in	40,000.	The	 literature	gives	
moreover	 some	 comparisons	 between	AOS	 and	 EOS	 and	 indicates	
EOS	 to	have:	higher	 suicidality	and	more	depressive	symptoms	 (Joa	
et	al.,	2009),	poorer	outcomes	(Diaz-Caneja	et	al.,	2015),	and	longer	
duration	of	untreated	psychosis	(DUP;	Joa	et	al.,	2009;	Schimmelmann	
et	al.,	2007).	The	DUP	is	commonly	defined	as	the	time	interval	be-
tween	 onset	 of	 positive	 psychotic	 symptoms	 and	 first	 adequate	
treatment	 (McGlashan,	1999),	but	DUP	according	to	age	at	onset	 in	
schizophrenia,	has	rarely	been	studied	(see	Table	1),	in	particular	with	
VEOS.	Meta-analyses	and	systematic	reviews	have	demonstrated	re-
lationship	between	 long	DUP	and	poor	outcome	 in	 the	 first	year	of	
illness	(Marshall	et	al.,	2005;	Perkins,	Gu,	Boteva,	&	Lieberman,	2005),	
as	well	 as	 in	 longer-term	outcome	 (Penttila,	 Jaaskelainen,	Hirvonen,	
Isohanni,	 &	Miettunen,	 2014;	 Perkins	 et	 al.,	 2005).	 Boonstra	 et	 al.	
(2012)	highlighted	less	severe	negative	symptoms	at	short	and	long-
term	 follow-up,	 especially	when	 the	DUP	 is	 less	 than	 nine	months.	
Consequently,	an	examination	of	the	DUP,	and	its	reduction	(an	inter-
national	goal	in	World	Health	Organization,	2011),	may	have	import-
ant	 implications	for	the	clinical	management	of	patients	(Fond	et	al.,	
2018).	Finally,	the	study	of	the	age	at	onset	could	also	be	used	to	iden-
tify	schizophrenia	subtypes	 (Gordon	et	al.,	1994;	Werry,	1992)	 thus	
distinguishing	more	 homogeneous	 subgroups	 of	 patients,	 especially	
and	8.1	years	±	5.7	vs.	1.0	years	±	2.5),	more	severe	symptomatology	(PANSS	Positive 
And Negative Syndrome Scale	scores),	and	lower	educational	level	than	the	AOS	group.	
In	addition,	 the	VEOS	subgroup	had	a	more	frequent	childhood	history	of	 learning	
disabilities	and	lower	prevalence	of	right-handedness	quotient	than	the	AOS.
Conclusion: The	study	demonstrates	the	existence	of	an	increased	gradient	of	clinical	
severity	from	AOS	to	VEOS.	In	order	to	improve	the	prognosis	of	the	early	forms	of	
schizophrenia	and	to	reduce	the	DUP,	clinicians	need	to	pay	attention	to	the	prodro-
mal	manifestations	of	the	disease.
K E Y W O R D S
adult-onset	schizophrenia,	duration	of	untreated	psychosis,	early-onset	schizophrenia,	
symptomatology,	very	early-onset	schizophrenia
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in	genetic	studies	 (Ahn,	An,	Shugart,	&	Rapoport,	2016;	Rapoport	&	
Inoff-Germain,	2000;	Schürhoff	et	al.,	2004).	Overall,	identifying	dif-
ferences	 in	 the	presentation	of	VEOS,	EOS,	 and	AOS	may	have	 im-
portant	 implications	 for	 a	better	description	of	 the	disease,	 thereby	
improving	 the	 possibility	 of	 precision	medicine	 for	 clinically	 defined	
homogeneous patient subgroups.
1.1 | Aims of the study
The	 objective	 of	 the	 present	 study	 was	 to	 compare,	 for	 the	 first	
time	 with	 the	 consensual	 definition,	 the	 clinical	 presentation	 of	
EOS/VEOS	with	 AOS,	 in	 a	 large	 multicentric	 sample	 of	 stabilized	
subjects	 with	 schizophrenia.	We	 hypothesized	 that	 EOS	 patients,	
TA B L E  1  Comparative	studies	according	to	age	at	onset	schizophrenia
Name Origin Population: age at onset Methods Results
Sato	et	al.	
(2004)
Munich,	Germany 473	neuroleptic	naive	
SCZ	(ICD-10)
Two	groups/onset:	Group	
1 < 40 years or younger, 
N	=	418
Group	2	>	41	or	older,	
N = 55
German	instru-
ment	=	AMDP;	GAF
Group	2:	lower	score	on	affective	flatten-
ing/social withdrawal; higher persecution.
Ballageer	et	al.	
(2005)
Manitoba, 
Québec,	Canada
242	FEP
Two	groups/onset:	
15–18	years,	N	=	82
19–30	years,	N = 119
DUP,	SAPS,	SANS,	ESRS,	
Calgary;	Toxic,	PAS,	
GAF
For	EOS,	longer	DUP	(mean	103.57	weeks	
vs.	46.31),	higher	negative	symptoms
White et al. 
(2006)
Minnesota, Iowa, 
USA
188	SCZ	(DSM	III,	III-R)
Two	groups/onset:	Group	
1 < 20 years, N = 49
Group	2	≥	20	years,	
N = 139
CASH,	SAPS,	SANS,	neu-
ropsychological battery
Group	1:	longer	DUP	(mean	2.4	years	
versus	1.3	years,	greater	motor	deficits,	no	
difference/measure	of	negative,	disorgan-
ized,	psychotic	symptoms.
Biswas	et	al.	
(2006)
Chandigarh, India 55	SCZ	(ICD	10)
Three	groups/onset:	
<14	years	Group	1,	
N = 15
14	≤	Group	2	<	18	years,	
N = 20
Group	3	≥	18	years,	
N = 20
IQ,	memory	and	percep-
tuor evaluation
Greater	deficits	in	VEOS	with	decreased	
gradient	of	severity	to	EOS	and	AOS
Biswas	et	al.	
(2007)
IRAOS	=	Instrument	
for	Retrospective	
Assessment	for	Onset	of	
SCZ,	PANSS,	NSS
NSS	more	frequent	in	VEOS	(100%),	and	
EOS	(90%)	than	in	AOS	patients	(55%).
Schimmelmann	
et	al.	(2007)
Australia,	
Germany,	
Switzerland
636	FEP	(DSM	IV)	in	
EPPIC	in	Melbourne
Two	groups/onset:	Group	
1	<	18	years,	N	=	118
Group	2	≥	18	y,	N = 519
SCID,	DUP	scale,	GAF,	
PAS
Group	1:	worse	premorbid	functioning,	
longer	DUP	(median	26.3	weeks	vs.	8.7)
Luoma	et	al.	
(2008)
Oulu, Finland 98	SCZ	(DSM	III-R)
2 groups/onset: 
14–22	years,	N = 52
23–31	years,	N	=	46
OCCPI	=	Operational	
Criteria	Checklist	for	
Psychotic	Illness
For	younger	patients:	inappropriate	affects,	
positive thought disorder, deterioration 
from	premorbid	level	of	function
Joa	et	al.	(2009) Stavanger,	
Norway
232	FEP	with	145	SCZ	
(DSM	IV)
Two	groups:	
Teens	<	18	years,	N = 43
Adults	≥	18	years,	N	=	189
SCID,	PANSS,	GAF,	PAS,	
drug abuse
Teens:	longer	DUP	(mean	77	weeks	vs.	
33.2),	worse	premorbid	functioning,	better	
PANSS	cognitive	scores	and	more	depres-
sive symptoms.
Holmén	et	al.	
(2012)
Oslo,	Norway 110	SCZ	(DSM	IV)
Two	groups/onset:	
12	<	Group	1	<	18	years,	
N = 20
18	≤	Group	2	<	65	years,	
N = 90
SCID,	PANSS,	PAS,	
neuropsychological 
evaluation
Group	1:	higher	negative	PANSS	score	and	
worse premorbid adjustment.
No	difference	in	executive	function	be-
tween two groups
Abbreviations:	AMDT,	Arbeitsgemeinschaft	für	Methodik	und	Dokumentation	in	der	Psychiatrie;	Calgary	Depression	Scale;	CASH,	Comprehensive	
Assessment	of	Symptoms	and	Severity;	DSM,	Diagnostic	and	Statistical	Mental	disorders;	DUP,	Duration	of	Untreated	Psychosis;	EPPIC,	Early	
Psychosis	Prevention	and	Intervention	Center;	ESRS,	Extrapyramidal	Symptom	Rating	Scale;	FEP,	First	Episode	Psychosis;	GAF,	Global	Assessment	
of	Functioning	Scale;	ICD-10,	International	Classification	of	Diseases	10th;	NSS,	Neurological	Soft	Signs;	PANSS,	Positive	And	Negative	Syndrome	
Scale;	PAS,	Premorbid	Adjustment	Scale;	SANS,	Scale	for	Assessment	of	Negative	Symptoms;	SAPS,	Scale	for	Assessment	of	Positive	Symptoms;	
SCZ,	Schizophrenia.
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especially	VEOS,	would	have	a	more	severe	clinical	symptomatology	
with	poorer	premorbid	adjustment,	longer	DUP,	and	lower	cognitive	
functioning,	in	comparison	with	AOS	patients.
2  | METHODS
2.1 | Subjects
The	 FACE-SZ	 (FondaMental	 Academic	 Centers	 of	 Expertise	 for	
Schizophrenia)	 cohort	 is	 based	 on	 a	 French	 national	 network	 of	
10	 Schizophrenia	 Expert	 Centers	 (Bordeaux,	 Clermont-Ferrand,	
Colombes,	Créteil,	Grenoble,	Lyon,	Marseille,	Montpellier,	Strasbourg,	
Versailles),	set	up	by	a	scientific	cooperation	foundation	in	France,	the	
FondaMental	Foundation	(www.fonda	tion-fonda	mental.org)	and	cre-
ated	by	the	French	Ministry	of	Research	in	order	to	create	a	platform	
that	links	healthcare	and	research	(Schürhoff	et	al.,	2015).
2.2 | Inclusion criteria
Consecutive	clinically	stable	patients	(defined	by	no	hospitalization	
and	 no	 treatment	 changes	 during	 the	 4	weeks	 before	 evaluation)	
with	a	DSM	IV-TR	diagnosis	of	schizophrenia	or	schizoaffective	dis-
order	were	included	in	the	study	between	2010	and	2017.	The	sam-
ple	was	divided	into	three	groups	of	age	at	onset	(AOS,	EOS	groups,	
and	 VEOS	 subgroup	 according	 to	 classical	 cutoff	 values).	 Age	 at	
onset	schizophrenia	was	defined	as	the	age	at	which	the	patient	first	
met	DSM	 IV-TR	 criteria	 for	 schizophrenia.	 To	 limit	 the	 recall	 bias,	
this	age	was	defined	with	the	help	of	the	patient,	his/her	family,	his/
her	 referring	psychiatrist,	 and	with	 the	use	of	medical	 case	notes.	
All	study	participants	were	referred	by	their	general	practitioner	or	
psychiatrist,	who	subsequently	received	a	detailed	evaluation	report	
with	suggestions	for	personalized	interventions.
2.3 | Clinical data
Patients	were	interviewed	by	members	of	the	specialized	multidis-
ciplinary	 team	 of	 the	 Expert	 Center.	 Diagnostic	 interviews	 were	
carried	out	by	two	independent	psychiatrists	of	the	same	center,	ac-
cording to the Structured Clinical Interview for Mental Disorders	(SCID	
2.0;	 First,	 Spitzer,	 Gibbon,	 &	 Williams,	 1997).	 Information	 about	
age	at	onset,	age	at	assessment,	age	at	first	treatment,	duration	of	
the disease, symptomatology, somatic diseases, comorbidities, and 
treatments	was	recorded.	The	DUP	was	calculated	as	 in	the	refer-
ence	article	(see	above	McGlashan,	1999).	Symptoms	of	schizophre-
nia were assessed using the Positive and Negative Syndrome Scale for 
Schizophrenia	(PANSS;	Kay,	Fiszbein,	&	Opfer,	1987).	The	level	of	de-
pression	in	schizophrenia	was	measured	with	the	Calgary Depression 
Rating Scale for Schizophrenia	 (CDRS;	 Addington,	 Addington,	
Maticka-Tyndale,	 &	 Joyce,	 1992).	 Therapeutic	 drug	 classes	 (first-
generation	 antipsychotic	 (FGA)/second-generation	 antipsychotic	
(SGA);	 antidepressant;	 anxiolytic;	 anticholinergic;	 antimanic	 agent;	
hypnotic)	 were	 recorded,	 and	 the	 presence	 of	 an	 extrapyramidal	
syndrome	was	evaluated	with	10	questions	of	the	French	version	of	
Neurological Soft Signs Scale	(Krebs,	Gut-Fayand,	Bourdel,	Dischamp,	
&	 Olié,	 2000).	 We	 also	 used	 the	 Edinburgh Handedness Inventory 
(Oldfield,	1971),	a	measurement	scale	 in	order	to	assess	the	domi-
nance	of	a	person's	right	or	 left	handedness	in	everyday	activities.	
This	 provides	 a	 quotient	 of	 laterality	 (positive	 for	 right-handers,	
negative	for	 left-handers).	Finally,	 the	Global Functional Assessment 
Scale	(GAF;	Bodlund	et	al.,	1994;	Endicott,	Spitzer,	Fleiss,	&	Cohen,	
1976),	which	is	a	DSM	IV	numerical	scale	with	a	range	from	0	to	100,	
was	used	to	assess	the	participants	psychological,	social,	and	profes-
sional	functioning.
2.4 | Neuropsychological measures
We used the Wechsler Adult Intelligence Scale	 (Wechsler,	 2008),	
which	provides	a	measure	of	general	 intellectual	 function	 in	older	
adolescents	 and	 adults.	 As	 data	 from	 both	WAIS-III	 and	WAIS-IV	
were available, we applied a correction algorithm to pool the results. 
Lichtenberger	and	Kaufman	(2009)	defined	the	standard	score	dif-
ference	when	both	versions	are	administered	to	the	same	subjects.	
To	pool	the	data,	we	created	a	fused	WAIS	FSIQ	variable,	taking	into	
account	this	correction.	The	seven	subtest	short	form	(Bulzacka	et	
al.,	2016)	was	used	to	estimate	the	Full	Scale	IQ	(FSIQ),	comprised	of	
the	following	subtests	and	cognitive	areas:	Picture	Completion	(vis-
ual	exploration	and	detail	perception),	Digit-Symbol	Coding	(visual-
motor	coordination,	motor,	and	mental	speed),	Similarities	(abstract	
verbal	reasoning),	Arithmetic	(mathematical	problem	solving),	Matrix	
Reasoning	 (nonverbal	 abstract	 problem	 solving,	 inductive	 spatial	
reasoning),	Digit	span	(attention,	working	memory,	mental	control),	
Information	(degree	of	general	information	acquired	from	culture).
We also used the National Adult Reading Test	 (Mackinnon	 &	
Mulligan,	2005;	Nelson	&	O'Connell,	1978)	which	consists	of	a	list	of	
40 phonetically irregular words that participants were asked to read 
aloud.	The	total	raw	score	ranges	from	0	to	40	and	was	included	in	
regression	equations	to	provide	an	estimate	of	premorbid	 intellec-
tual ability.
Finally,	the	history	of	learning	disabilities	was	explored	during	
the	 neuropsychological	 evaluation	 by	 asking	 a	 single	 question:	
“have you had learning disabilities” with a dichotomous response 
(yes/no).
2.5 | Ethical concerns
The	 study	was	 carried	 out	 in	 accordance	with	 ethical	 principles	 for	
medical	research	involving	humans	(WMA,	Declaration	of	Helsinki).	All	
data	were	collected	anonymously.	As	this	study	includes	data	coming	
from	regular	care	assessments,	a	nonopposition	form	was	signed	by	
all	participants,	all	being	adults	at	the	time	of	the	assessment.	A	web-
based	application	was	developed	to	collate	assessment	data	for	clinical	
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monitoring	ad	research	purposes.	Access	to	the	system	was	carefully	
regulated,	and	approval	was	obtained	from	the	Committee	in	charge	of	
the	safety	of	computerized	databases	(CNIL	DR	2012-157).
2.6 | Statistical analysis
Subjects	were	first	divided	into	two	groups	and	compared:	AOS,	onset	
at	or	over	the	age	of	18	and	EOS,	onset	strictly	before	the	age	of	18.	
Second,	 specific	 characteristics	were	 sought	 in	 the	VEOS	 subgroup	
(onset	strictly	before	the	age	of	13),	which	was	initially	included	within	
the	EOS	group.	Three	groups,	VEOS,	EOS,	and	AOS,	were	therefore	
compared.	 Analyses	 were	 conducted	 using	 SAS	 (release	 9.4;	 SAS	
Statistical	Institute).	Socio-demographic,	treatment,	clinical,	and	neu-
ropsychological	characteristics	are	presented	using	measures	of	means	
and	dispersion	(standard	deviation)	for	continuous	data	and	frequency	
distribution	 for	 categorical	 variables.	 Comparisons	 between	 groups	
were	performed	using	the	chi-square	test	or	Fisher's	exact	test	for	cat-
egorical	variables.	Continuous	variables	were	analyzed	with	Student's	
t	 tests	 for	normally	distributed	data	 and	with	 the	Wilcoxon–Mann–
Whitney	tests	in	case	of	normality	violation.
Variables	 significantly	 associated	 in	 univariate	 analysis	 were	
included in the multivariate logistic regression model to estimate 
the	 likelihood	that	VEOS	and	EOS	were	associated	with	each	 fac-
tor.	 DUP,	 level	 of	 education,	 duration	 of	 the	 disease	 ≥	 5	 years,	
PANSS	>	70	“mildly to moderate ill”	(Leucht	et	al.,	2005;	Suzuki	et	al.,	
2015),	and	GAF	with	three	steps	(100–71	“no to slight functional im-
pairment”;	70–51	“mild/moderate functional impairment”; and <51 “se-
rious functional impairment”	APA,	2000)	were	studied	in	the	model.
To	estimate	the	relationships	between	age	at	onset	and	DUP,	and	
between	DUP	and	PANSS	scores,	Pearson's	correlation	coefficient	
was	used	for	normally	distributed	data	and	Spearman's	correlation	
coefficient	for	non-normally	distributed	data.
3  | RESULTS
A	 sample	 of	 727	 individuals	 with	 stable	 schizophrenia,	 enrolled	 in	
FACE-SZ	cohort,	was	included	in	this	study.	The	sample	was	composed	
of	539	(74%)	males	and	188	(26%)	females.	The	mean	age	at	assessment	
was	32.2	±	9.7	years,	with	a	mean	age	at	onset	of	21.6	±	6.5	years.	First,	
individuals	with	early-onset	schizophrenia	(EOS,	N	=	176)	were	com-
pared	 to	 individuals	with	 adult-onset	 schizophrenia	 (AOS,	N	 =	 551).	
Table	2	 shows	 clinical	 and	neuropsychological	 characteristics	of	 the	
sample.	Second,	we	analyzed	data	from	the	subsample	with	very	early-
onset	schizophrenia,	(VEOS,	N	=	22).	Clinical	and	neuropsychological	
characteristics	of	the	three	groups	are	detailed	in	Table	3.
3.1 | EOS compared to AOS
On	the	one	hand,	there	was	no	statistically	significant	difference	be-
tween	EOS	and	AOS	across	a	number	of	variables,	including	type	of	
disorder	 (schizophrenia	vs.	 schizoaffective	disorder),	gender,	 treat-
ment	(psychotropic	class),	somatic	antecedent	(allergy,	neurological,	
endocrinological),	level	of	depression,	functioning,	neuropsychologi-
cal	soft	signs,	and	neuropsychological	evaluation	(Table	2).
On	the	other	hand,	DUP	and	PANSS	scores	were	more	relevant	
to	observe	between	EOS	and	AOS.	The	mean	DUP	was	1.6	years	
longer	 in	EOS,	 versus	AOS,	 group	 (2.6	±	4.1	years	 vs.	1.0	±	2.5;	
p	<	.0001).	The	EOS,	versus	AOS,	group	had	higher	PANSS	scores,	
especially	significantly	higher	PANSS	negative	score	(20.9	±	8.2	vs.	
19.8	±	8.0,	p	=	.017),	psychopathology	general	score	(37.4	±	10.3	vs.	
35.1	±	10.3;	p	=	.005),	and	total	score	(74.4	±	18.7	vs.	70.2	±	19.5;	
p	=	 .013).	About	 the	small	difference	on	negative	 symptoms	be-
tween	EOS	and	AOS,	but	significant,	the	effect	size	(Cohen's	d)	for	
this	difference	is	0.15,	which	correspond	to	small	effect.	Note	also	
that	even	the	PANSS	total	score	was	significantly	higher	for	EOS	
than	AOS,	the	GAF	interval	was	the	same	(41–50)	with	a	significa-
tion	of	“serious symptoms or any serious impairment in social, occupa-
tional, or school functioning”	(2),	regardless	of	onset	schizophrenia.
Educational	level	was	at	last	significantly	lower	in	the	EOS,	ver-
sus	AOS,	group	(11.1	±	2.4	years	vs.	12.6	±	2.8	years;	p	<	.0001),	and	
even	if	there	was	no	significant	difference	in	the	neuropsychological	
evaluation	between	EOS	and	AOS	groups	 (see	Table	2),	 it	was	 in-
teresting	to	note	that	there	was	no	difference	in	the	premorbid	IQ	
scores between the two groups.
3.2 | VEOS compared to EOS and AOS
The	VEOS	subgroup	had	an	almost	fourfold	longer	DUP	than	the	EOS	
group	(8.1	±	5.7	years	vs.	1.8	±	3.1;	p	<	.0001)	and	an	eightfold	longer	
DUP	than	the	AOS	group	 (8.1	±	5.7	years	vs.	1.0	±	2.5;	p	<	 .0001).	
The	VEOS	subgroup,	versus	EOS	and	AOS	groups,	respectively,	also	
had	significantly	higher	PANSS	scores	for	 the	psychopathology	gen-
eral	score	(39.6	±	8.8	vs.	37.1	±	10.5	and	35.1	±	10.3;	p	=	.021)	and	
total	 score	 (76.2	±	15.6	vs.	74.2	±	19.1	 and	70.2	±	19.5;	p = .041; 
Table	 3).	 Similarly,	 educational	 level	 was	 significantly	 lower	 in	 the	
VEOS	 subgroup	 than	 EOS	 group	 and	AOS	 group	 (10.5	 ±	 2.4	 years	
vs.	11.2	±	2.4	years	and	12.6	±	2.8	years;	p	<	.0001;	Table	3).	There	
were	 no	 significant	 differences	 in	 neuropsychological	 scores	 among	
the	 three	 groups	 (Table	 3),	 and	 it	was	 also	 interesting	 to	 note	 that	
there	was	no	difference	in	the	premorbid	IQ	scores	between	the	three	
groups,	although	the	VEOS	subgroup	exhibited	(a)	more	evidence	of	
a	history	of	 learning	disabilities	 than	 the	AOS	group	 (25%	vs.	9.2%;	
p	=	.020)	and	(b)	lower	right-handedness	quotient	than	the	AOS	group	
(36.2	±	68.25	vs.	62.22	±	53.34;	p	=	.048).
3.3 | Multivariate analysis
After	 taking	 into	 account	 potential	 confounders,	 the	 risk	 of	 having	
early	onset	is	significantly	associated	with	higher	DUP,	lower	education	
level,	and	higher	severity	of	the	disease	(PANSS	>	70).	See	Figure	1.
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3.4 | Correlation
A	negative	 correlation	was	 found	between	 age	 at	 onset	 and	DUP	
(ρ	=	−226,	p	<	 .001),	while	DUP	was	not	correlated	 to	any	PANSS	
scores	 across	 all	 groups	 (AOS	 group,	 EOS	 group	 with	 or	 without	
VEOS	subgroup,	isolated	VEOS	subgroup,	or	total	population).
4  | DISCUSSION
The	main	objective	of	the	present	study	was	to	compare	the	pres-
entation	of	EOS/VEOS	with	AOS,	making	the	assumption	that	EOS	
patients,	especially	VEOS,	would	have	a	greater	 severity	of	 symp-
tomatology	with	poorer	premorbid	adjustment,	a	 longer	DUP,	and	
lower	 cognitive	 functioning.	 The	 results	 confirm	 several	 of	 this	
study's	hypotheses	and	results	of	univariate	analyses	are	corrobo-
rated	by	multivariate	analyses.	The	EOS	group	and	VEOS	subgroup	
both	 had	 more	 severe	 symptomatology	 (especially	 the	 general	
PANSS	 score),	 a	 poorer	 premorbid	 adjustment	 with	 lower	 educa-
tional	level	and	longer	DUP	than	the	AOS	group.	However,	a	lower	
cognitive	 functioning	was	not	significantly	 found	among	the	 three	
groups;	 the	 VEOS	 subgroup	 had	 only	 a	 more	 frequent	 history	 of	
learning	disabilities	and	lower	prevalence	of	right-handedness	quo-
tient	than	the	AOS.
First,	 comparisons	 between	 EOS	 and	 AOS	 groups	 showed	
greater	severity	in	the	EOS	group,	with	this	EOS	group	showing	lon-
ger	DUP	and	higher	PANSS	scores.	Our	results	are	consistent	with	
previous	 studies	 carried	 out	 in	 different	 countries	 (see	Table	 1).	
The	longer	DUP	for	the	EOS,	versus	AOS,	group:	2.6	years	versus.	
1.0 year in the current study is similar to previous investigations: 
a	mean	103.57	weeks	(2.0	years)	versus.	46.31	weeks	(0.9	years)	
in	Ballageer	et	al.	 (2005);	2.4	years	versus.	1.3	years	 in	White	et	
al.	(2006);	and	77	weeks	(1.5	years)	versus	33.2	weeks	(0.6	years)	
in	Joa	et	al.	(2009).	In	regard	to	the	PANSS	scores,	the	EOS	group	
had	a	higher	PANSS	negative	score,	compared	to	the	AOS	group,	
which is in accord with the two published studies that have in-
vestigated	 this,	 namely	 Ballageer	 et	 al.	 (2005)	 and	 Biswas	 et	 al.	
(2007)	(Table	1).	An	increased	level	of	severity	on	the	PANSS	psy-
chopathology	general	score	has	also	previously	been	found	in	the	
EOS,	versus	AOS	group	 (Biswas	et	al.,	2007).	 In	contrast,	no	sig-
nificant	difference	on	PANSS	negative	score	was	found	according	
to	age	at	onset	in	schizophrenia	in	some	previous	studies	(Biswas	
et	al.,	2007;	Schimmelmann	et	al.,	2007).	In	the	current	study,	the	
PANSS-positive	score	showed	no	significant	differences	between	
groups,	 as	 in	previous	 studies	 (Ballageer	et	al.,	2005;	Holmén	et	
al.,	 2012;	 Joa	 et	 al.,	 2009;	White	 et	 al.,	 2006).	 These	data	were	
finally	 relevant	 in	confrontation	with	 the	 literature;	 in	particular,	
in	 the	meaning	 of	 the	PANSS	 (Leucht	 et	 al.,	 2005;	 Suzuki	 et	 al.,	
2015):	In	40	articles	(N	=	8,000),	cross-sectional	data	on	the	GAF	
and	 PANSS	 (Suzuki	 et	 al.,	 2015)	 at	 study	 baseline	 or	 its	 equiva-
lent	were	close	to	our	study	with	a	GAF	mean	score	=	49.8	(in	our	
study,	 46.22	 for	 EOS	 group,	 vs.	 49.48	 in	 AOS)	 and	 PANSS	 total	
score	=	76.9	(in	our	study,	74.4	for	EOS	group,	vs.	70.2	in	AOS).
Second,	 from	VEOS	 to	EOS	 to	AOS	groups,	 there	was	 also	 an	
increase	 in	 severity,	with	 longer	DUP	 (8.1	 years	 vs.	 1.8	 years	 and	
1.0	 years	 respectively)	 and	 more	 pronounced	 symptomatology	
(psychopathology	 general	 PANSS	 score	 and	 total	 PANSS	 score).	
Although	DUP	has	been	previously	investigated	in	EOS	(Diaz-Caneja	
et	 al.,	 2015;	 Joa	 et	 al.,	 2009;	 Stentebjerg-Olesen,	 Pagsberg,	 Fink-
Jensen,	 Correll,	 &	 Jeppesen,	 2016),	 the	 present	 study	 is	 the	 first	
to	examine	DUP	 in	VEOS	patients.	This	 could	be	partly	 explained	
by	 the	 difficulty	 in	 diagnosing	 childhood	 schizophrenia	 (Gochman	
et	al.,	2011).	For	example,	 in	the	first	study	(McKenna	et	al.,	1994)	
investigating	 a	 cohort	 of	 childhood	onset	 schizophrenia	 (COS),	 in-
cluded	male	and	female	patients	aged	6–18	years,	with	criteria	for	
schizophrenia	 and	onset	 at/or	 before	12	 years,	 the	protocol	 is	 in-
dicative	of	the	difficulty	in	the	investigation	of	COS.	Following	over	
450	phone	calls,	260	patients	were	reviewed,	with	71	selected	and	
only	19	children	(27%)	being	diagnosed	with	COS.	Moreover	in	chil-
dren	and	teenagers,	time	is	required	to	check	diagnosis	reliability	as	
well	as	to	prepare	the	families	for	the	consequences	of	the	diagno-
sis.	 Such	 factors	 contribute	 to	 the	 longer	DUP,	 and	 its	 associated	
deleterious	consequences	(Jeppesen	et	al.,	2008)	on	relational	and	
functional	life	in	patients	and	caregivers.	Improving	early	diagnosis	
in	schizophrenia	is	consequently	an	important	challenge	with	course	
and	functional	implications.
Several	countries	have	developed	early	intervention	programs	in	
order	to	enhance	detection	in	first-episode	psychosis:	USA,	RAISE-
ETP	 (Recovery After an Initial Schizophrenia Episode–Early Treatment 
Program);	Australia	(EPPIC,	Early Psychosis Prevention and Intervention 
Centre service);	 Canada	 (PEPP,	 Prevention and Early Intervention 
Program for Psychoses);	 Scandinavia	 (early	 TIPS	 Treatment and 
Intervention in Psychosis);	Singapore	(EPIP,	Early Psychosis Intervention 
Program);	United	Kingdom	 (STEP-ED,	Specialized Treatment Early in 
Psychosis-Early Detection).	Consequently,	there	 is	a	growing	aware-
ness	of	this	area	as	a	public	health	problem	(Rubio	&	Correll,	2017).
In	the	present	study,	it	was	hypothesized	that	an	increasing	se-
verity	would	be	evident	in	PANSS	negative	scores	from	VEOS	to	EOS	
and	AOS	groups,	as	seen	in	Biwas	et	al.	in	2007	(p	<	.001).	However,	
the	results	did	not	support	this	hypothesis.	This	may	be	explained	
by	a	type	II	error.	The	high	levels	of	negative	symptoms	in	EOS	and	
VEOS	subgroups	could	also	be	due	 in	part,	 to	 secondary	negative	
symptoms	induced	by	higher	doses	of	antipsychotic	medication,	es-
pecially when positive symptoms are very present. Conversely, the 
absence	of	differences	between	groups	for	the	positive	dimension	of	
the	PANSS	could	be	explained	by	the	low	temporal	stability	of	this	
dimension	and	the	Expert	Center	inclusions	were	based	on	clinically	
stable	patients.	Previous	investigations	have	showed	a	relationship	
between	negative	symptoms	and	poor	prognosis	(Fleischhaker	et	al.,	
2005;	Vyas,	Hadjulis,	Vourdas,	Byrne,	&	Frangou,	2007),	and	more	
recently the association between negative symptoms and longer 
DUP	(Boonstra	et	al.,	2012;	Murru	&	Carpiniello,	2018;	Perkins	et	al.,	
2005),	so	it	would	be	interesting	to	verify	the	results	by	increasing	
the	 size	of	 the	EOS	group/VEOS	subgroup.	Furthermore,	 a	 recent	
work	indicated	that	aspects	of	negative	symptoms	may	have	a	rele-
vant intestinal mucosal immune system impact on their etiology and 
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TA B L E  2  Clinical	and	neuropsychological	characteristics	of	the	patients	according	to	age	at	onset	schizophrenia	(EOS	with	VEOS/AOS)
Characteristics VEOS + EOS <18 years (N = 176) AOS ≥ 18 years (N = 551) p (α = 5%)
Type	of	disorder	(N	=	727)
Schizophrenia,	N	(%) 135	(76.7) 414	(75.1) .631	(χ2	0.921)
Schizoaffective	disorder,	N	(%) 37	(21.0) 129	(23.4)
Schizophreniform	disorder,	N	(%) 4	(2.3) 8	(1.5)
Gender
Men, N	(%)/Women,	N	(%) 130	(73.9)/46	(26.1)i 409	(74.2)/142	(25.8) .921	(χ2	0.009)
(♂/♀) 2.8/1 2.9/1
Characteristics	of	age
Age	at	assessment	(mean	years	±	SD) 26.9	±	7.9 33.9	±	9.7 <.0001	(Z	−8.897)
Age	at	onset	schizophrenia	(mean	
years	±	SD)
15.1	±	2.5 23.7	±	5.9 <.0001	(Z	−20.029)
Age	at	first	treatment	(mean	years	±	SD) 17.5	±	4.1 23.9	±	6.9 <.0001	(Z	−15.169)
Duration	of	the	disease	(mean	
years	±	SD)
11.8	±	7.8 10.3	±	8.4 .0042	(Z	2.86)
DUP	(mean	years	±	SD) 2.6	±	4.1 1.0	±	2.5 <.0001	(Z	5.401)
Level	of	education	(mean	years	±	SD) 11.1	±	2.4 12.6	±	2.8 <.0001	(Z	−5.767)
Treatment
Neuroleptic/antipsychotic,	N	(%) 140	(79.5) 447	(81.1) .644	(χ2	0.214)
Antidepressant 47	(26.7) 141	(25.6) .769	(χ2	0.086)
Anxiolytic 45	(25.6) 134	(24.3) .738	(χ2	0.112)
Anticholinergic 34	(19.3) 80	(14.5) .127	(χ2	2.324)
Antimanic	agent 23	(13.1) 82	(14.9) .551	(χ2	0.355)
Hypnotic 17	(9.7) 48	(8.7) .701	(χ2	0.147)
Somatic	antecedent
Allergy,	N	(%) 51	(31.1) 144	(27.4) .363	(χ2	0.829)
Neurological
Headache,	N	(%) 21	(12.7) 60	(11.7) .735	(χ2	0.115)
Epilepsy,	N	(%) 8	(4.9) 21	(4.0) .617	(χ2	0.250)
Cranial trauma, N	(%) 16	(10.0) 66	(12.8) .345	(χ2	0.892)
Endocrinological
Diabetes, N	(%) 7	(4.3) 16	(3.1) .455	(χ2	0.557)
Dysthyroidism, N	(%) 8	(5.0) 19	(	3.7) .463	(χ2	0.538)
Dyslipidemia, N	(%) 13	(8.2.) 81	(15.8) .015	(χ2	5.923)
Dermatological
Acne,	N	(%) 32	(19.6) 70	(13.5) .06	(χ2	3.682)
Eczema,	N	(%) 16	(9.9) 46	(8.9) .690	(χ2	0.159)
Hair	loss,	N	(%) 4	(2.5.) 40	(7.7) .017	(χ2	5.650)
PANSS
Positive	score	(mean	±	SD) 15.3	±	5.4 14.6	±	5.7 .182	(F	1.782)
Negative	score	(mean	±	SD) 20.9	±	8.2 19.8	±	8.0 .017	(Z	2.39)
Psychopathology	general	score	
(mean	±	SD)
37.4	±	10.3 35.1	±	10.3 .005	(Z	2.84)
Total	score	(mean	±	SD) 74.4	±	18.7 70.2	±	19.5 .013	(F	6.203)
Calgary	Scale	(mean	±	SD) 3.9	±	4.0 4.0	±	4.4 .854	(Z	0.18)
GAF	(mean	±	SD) 46.44	±	13.189 49.48	±	12.890 .913	(F	0.009)
(Continues)
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course,	highlighting	the	importance	of	a	more	holistic	perspective	on	
the	nature	of	the	pathophysiology	in	schizophrenia	(Kanchanatawan	
et	al.,	2018).
Thirdly,	a	lower	level	of	education	was	found	from	VEOS	to	AOS	
groups	(p	<	.0001)	and	this	result	could	be	explained	simply	by	an	
active	 onset	 of	 the	 disease	 earlier,	 thus	 disturbing	more	 studies.	
Nevertheless,	there	was	no	significant	difference	among	the	three	
groups	 regarding	 neuropsychological	 functioning	 (IQ,	 premorbid	
IQ).	On	the	one	hand,	similar	inclusion	criteria,	apart	from	the	age	
at	onset	schizophrenia	and	a	relatively	similar	duration	of	the	dis-
ease,	could	explain	these	similarities.	However,	in	particular	about	
premorbid	 IQ,	 the	 result	 might	 seem	 counterintuitive	 because	 it	
was	more	expected	a	lower	premorbid	IQ	in	EOS/VEOS	compared	
with	AOS,	in	relation	to	higher	neurodevelopmental	part.	With	our	
study,	 the	 result	might	 appear	 to	be	 in	 favor	of	 a	 little	 faster	de-
cline	 in	patients	with	EOS	compared	with	AOS	group;	hence,	 the	
importance	of	early	diagnosis,	early	management,	and	more	study	is	
needed.	On	the	other	hand,	in	our	work,	neurocognitive	functioning	
was	assessed	using	a	battery	of	neuropsychological	tests;	however,	
we	cannot	exclude	that	more	accurate	tests	could	lead	to	the	iden-
tification	of	subtle-specific	deficits.	In	the	literature	for	example,	a	
broad	question	is	if	the	deficit	was	present	early	or	was	associated	
with	a	decline,	or	 a	 cessation	of	 the	development	 (Kremen	et	 al.,	
2010).	As	we	observed,	Fujino	et	al.	(2017)	estimated	the	cognitive	
decline	in	patients	with	schizophrenia	and	showed	the	distribution	
of	approximately	70%	of	patients	had	a	deterioration.	In	White	et	
al.	 (2006),	when	 the	 developmental	 course	was	 controlled,	 there	
were	no	significant	differences	between	the	adolescent	and	adult	
patients'	 groups	 in	 any	 domains	 (language,	working	memory),	 ex-
cept	in	motor	function	where	adolescent	performance	was	worse.	
In addition, the type II error was also to be considered in our results.
However,	despite	 the	small	 sample,	 it	may	be	notable	 that	 the	
VEOS	subgroup	present	with:	(a)	a	more	extensive	history	of	learning	
disabilities	than	AOS	(p	=	.020);	(b)	a	lower	handedness	quotient	than	
AOS	(p	=	.048).	Even	if	these	results	need	to	be	checked	on	a	larger	
sample,	these	notions	of	learning	disability	and	handedness	quotient	
are	 in	 agreement	 with	 previous	 data	 (Alaghband-rad	 et	 al.,	 1995;	
Fleischhaker	et	al.,	2005;	Remschmidt	&	Theisen,	2012;	Röpcke	&	
Eggers,	2005).	 In	a	review	of	75	studies	 (Diaz-Caneja	et	al.,	2015),	
the	most	replicated	predictors	of	clinical,	 functional,	and	cognitive	
outcomes	 in	EOS	were	premorbid	difficulties	and	symptom	sever-
ity.	Thus,	poorer	premorbid	adjustment	from	VEOS	to	EOS	and	AOS	
reinforces	the	importance	of	early	screening	and	early	care.	Finally,	
as	previously	reported	(Biswas	et	al.,	2006;	Karp	et	al.,	2001;	Kumra	
et	al.,	2000),	our	results	support	the	neurodevelopmental	hypothe-
sis	in	the	VEOS	group,	as	indicated	by	a	history	of	learning	disabil-
ities	 and	 lower	 levels	of	handedness	 lateralization.	About	 cerebral	
development	 in	 fact,	 hand	 preference—or	 dominance—has	 been	
extensively	used	as	an	easy-to-measure	proxy	of	brain	asymmetry,	
since	it	has	been	regarded	as	a	manifestation	of	cerebral	dominance	
(Sommer,	Ramsey,	Kahn,	Aleman,	&	Bouma,	2001).	The	hemispheres	
of	 the	 human	 brain	 are	 anatomically	 and	 functionally	 asymmetric	
(Gazzaniga,	2005;	Oertel-Knochel	&	Linden,	2011).	The	loss	of	hemi-
spheric	lateralization	has	long	been	proposed	to	be	a	consequence	of	
disrupted neurodevelopment in individuals with psychotic disorder 
(Oertel-Knochel	&	Linden,	2011).
4.1 | Strengths
The	strengths	of	the	study	were	the	use	of	homogeneous	and	ex-
haustive	standardized	diagnostic	protocols	and	neuropsychological	
assessments in a large French national multicentric study, as well 
as	 the	use	of	hospital	 records	and	 interviews	with	patients,	 their	
families,	and	their	medical	referents,	especially	important	in	regard	
to	DUP	and	illness	history.	Our	study	is	one	of	the	most	important	
in	terms	of	total	sample	size	(see	Table	1),	with	the	largest	sample	of	
VEOS	published	to	date	with	a	validated	cutoff	to	define	VEOS	sub-
group.	Of	note,	this	 is	the	first	study	to	investigate	DUP	in	VEOS	
patients.	Data	on	VEOS	may	contribute	more	widely	to	an	under-
standing	of	the	pathophysiology	of	schizophrenia	and	therefore	to	
the	care	provided	to	patients.	Many	data	about	patients	with	EOS	
and	AOS	are	in	agreement	with	the	literature	(PANSS	scores,	DUP,	
IQ	and	premorbid	IQ),	which	guarantees	the	quality	of	the	study.
Characteristics VEOS + EOS <18 years (N = 176) AOS ≥ 18 years (N = 551) p (α = 5%)
Neurological	Soft	Signs
Extrapyramidal	score	(mean	±	SD) 0.264	(0.372) 0.261	(0.360) .876	(Z	0.16)
Neuropsychological	evaluation
Handedness	quotient	(mean	±	SD) 58.15	±	55.7 62.22	±	53.339 .420	(F	6.51)
Intellectual	quotient	7	subtests	WAIS	
short	form	(mean	±	SD)
82.73	±	15.659 84.36	±	15.235 .259	(F	1.275)
fNART-based	premorbid	IQ	
(mean	±	SD)
104.13	±	8.868 104.16	±	8.210 .963	(F	0.002)
Learning	disabilities,	n(%) 19	(12.8) 42	(9.2) .197	(χ2	1.662)
Abbreviations:	AOS,	Adult	Onset	Schizophrenia;	DUP,	Duration	of	Untreated	Psychosis;	EOS,	Early	Onset	Schizophrenia;	fNART,	French	National	
Adult	Reading	Test;	GAF,	Global	Assessment	of	Functioning;	IQ	Full,	Intelligence	Quotient;	VEOS,	Very	Early	Onset	Schizophrenia;	WAIS,	Wechsler	
Adult	Intelligence	Scale.
TA B L E  2   (Continued)
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4.2 | Limitations
As	the	patients	have	been	recruited	 in	different	centers,	we	can-
not	 rule	 out	 differences,	 but	meetings	 allowed	 us	 to	 standardize	
the	quotation	between	the	centers.	Particularly	 in	the	estimation	
of	the	age	at	onset,	we	chose	clinical	evaluation;	we	did	not	have	
an	additional	and	specific	tool	for	this	question.	To	circumvent	this	
point,	 we	 used	 several	 clinical	 sources	 (patient,	 exchanges	 with	
the	family,	treating	psychiatrist,	computerized	clinical	records	and	
files,	professional	letters)	to	define	the	age	which	the	patient	first	
met	DSM	IV-TR	criteria	for	schizophrenia.	All	the	psychiatrists	had	
the	 clinical	 recommendations	 of	 the	 evaluation	 for	 this	 specific	
TA B L E  3  Clinical	and	neurophychological	characteristics	of	the	patients	according	to	age	at	onset	schizophrenia	(VEOS,	EOS,	AOS)
Characteristics
VEOS < 13 years 
(N = 22)
13 
years ≤ EOS < 18 years 
(N = 154)
AOS ≥ 18 years 
(N = 551)
p global 
(α = 5%)
p
VEOS vs. 
EOS
p
VEOS vs. 
AOS
p
EOS vs. 
AOS
Type	of	disorder	(N	=	727)
Schizophrenia,	N	(%) 18	(81.8) 117	(76.0) 414	(75.1) .757 .878 .726 .600
Schizoaffective	disor-
der, N	(%)
4	(18.2) 33	(21.4) 129	(23.4)
Schizophreniform	disor-
der, N	(%)
0 4	(2.6) 8	(1.5)
Gender
Men, N	(%)/Women,	
N	(%)
14	(81.8)/8	(18.2) 116	(75.3)/38	(24.7) 409	(74.2)/142	
(25.8)
.501 .294 .324 .787
(♂/♀) 1.8	/1 3.1/1 2.9/1
Characteristics	of	age
Age	at	assessment	
(mean	years	±	SD)
24.1	±	6.2 27.3	±	8.0 33.9	±	9.7 <.0001 .06 <.0001 <.0001
Age	at	onset	schizo-
phrenia	(mean	
years	±	SD)
9.55	±	2.5 15.9	±	1.2 23.7	±	5.9 <.0001 <.0001 <.0001 <.0001
Age	at	first	treatment	
(mean	years	±	SD)
17.1	±	6.3 17.5	±	3.7 23.9	±	6.9 <.0001 .9 <.0001 <.0001
Duration	of	the	disease	
(mean	years	±	SD)
14.2	±	6.4 11.5	±	8.0 10.3	±	8.4 .0029 .0355 .0035 .0458
DUP	(mean	years	±	SD) 8.1	±	5.7 1.8	±	3.1 1.0	±	2.5 <.0001 <.0001 <.0001 <.0004
Level	of	education	
(mean	years	±	SD)
10.5	±	2.4 11.2	±	2.4 12.6	±	2.8 <.0001 .29 .002 <.0001
PANSS
Positive	score	
(mean	±	SD)
14.9	±	4.8 15.4	±	5.5 14.6	±	5.7 .388 .937 .975 .355
Negative	score	
(mean	±	SD)
20.7	±	7.2 20.9	±	8.4 19.8	±	8.0 .334 .996 .864 .325
Psychopathology	gen-
eral	score	(mean	±	SD)
39.6	±	8.8 37.1	±	10.5 35.1	±	10.3 .021 .556 .120 .085
Total	score	(mean	±	SD) 76.2	±	15.6 74.2	±	19.1 70.2	±	19.5 .041 .896 .343 .068
Neuropsychological	evaluation
Handedness	quotient	
(mean	±	SD)
36.2	±	68.249 61.29	±	53.237 62.22	±	53.339 .121 .076 .048 .797
Intellectual	Quotient,	
7	subtests	WAIS	
(mean	±	SD)
83.25	±	12.965 82.65	±	16.082 84.36	±	15.235 .523 .699 .913 .246
Fnart-based	premorbid	
IQ	(mean	±	SD)
102.37	±	9.447 104.38	±	8.790 104.16	±	8.210 .619 .291 .298 .873
Learning	disabilities,	
N	(%)
5	(25.0) 14	(10.9) 42	(9.2) .065 .080 .020 .066
Abbreviations:	AOS,	Adult	Onset	Schizophrenia;	DUP,	Duration	of	Untreated	Psychosis;	EOS,	Early	Onset	Schizophrenia;	fNART:	French	National	
Adult	Reading	Test;	IQ,	Intelligence	Quotient;	VEOS,	Very	Early	Onset	Schizophrenia;	WAIS,	Wechsler	Adult	Intelligence	Scale.
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question.	Moreover,	the	recall	bias	was	minimized	by	a	relative	ho-
mogeneous	age	at	assessment	(young	adult):	Mean	age	at	assess-
ment	was	younger	than	33	years	of	age,	so	in	general,	patients	were	
young enough to still have parents, relatives and a possible com-
puterized	file	with	professional	letters.	The	duration	of	the	disease,	
between	14.2	years	for	VEOS	and	10.3	years	for	AOS,	also	suggests	
all	 patients	had	 sufficient	 insight	 about	 the	onset	of	 the	disease,	
but	not	too	far	away	to	minimize	recall	bias.	These	elements	(rela-
tive	homogeneity	of	age	at	assessment	and	duration	of	the	disease)	
could	also	reinforce	the	estimation	of	premorbid	intellectual	ability.
We	have	a	large	nonselected	national	sample	of	727	individuals,	
but	with	three	groups	of	different	size,	particularly	VEOS	subgroup	
(which	also	emphasizes	the	importance	of	improving	the	diagnosis	of	
young	patients).	Therefore,	in	order	to	limit	statistical	errors	related	
to	the	small	VEOS	subgroup,	we	first	analyzed	the	main	groups,	AOS	
(N	=	551)	and	EOS	(N	=	176)	and	we	secondly	conducted	an	in-depth	
examination	 of	 the	 significant	 results.	 However,	 we	 had	 to	 spec-
ify	 this	 limitation	several	 times	 in	 the	 interpretation	of	our	 results	
(PANSS	results,	neuropsychological	evaluation).
Our	data	were	analyzed	in	a	cross-sectional	design,	with	a	sta-
bilized	 psychotic	 phenomenology	 and	 require	 now	 investigation	
within	a	longitudinal	design.	A	stable	condition	is	also	important	to	
note	 for	 the	 interpretation	of	 the	 clinic	 and	neuropsychology	 and	
could	also	mitigate	some	differences.	In	all	cases,	the	present	results	
may	indicate	VEOS	to	be	underdiagnosed	and	undertreated	in	child	
populations,	which	 requires	 investigation	 in	 future	 studies,	 as	 this	
help	to	reduce	DUP	and	improve	illness	prognosis.
In	 conclusion,	 the	 EOS	 group,	 especially	 the	 VEOS	 subgroup,	
exhibited	 longer	 DUP,	 more	 severe	 symptomatology	 and	 a	 lower	
educational	 level	 than	 the	 AOS	 group.	 The	 study	 demonstrated	
the	existence	of	an	increased	gradient	of	clinical	severity	from	AOS	
to	VEOS.	 In	 order	 to	 improve	 the	 prognosis	 of	 the	 early	 forms	of	
schizophrenia	and	to	reduce	the	DUP,	clinicians	need	to	pay	atten-
tion	to	the	prodromal	manifestations	of	the	disease.
Improving	early	diagnosis	and	organizing	targeted	programs	may	
be	crucial	to	the	management	and	outcome	of	EOS.	An	innovative	
and	multidisciplinary	public	health	approach	may	prove	of	utility,	in-
volving	care	and	educational	professionals,	as	well	as	the	patient's	
family.
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